Single-cell profiling guided combinatorial immunotherapy for fast-evolving CDK4/6 inhibitor resistant HER2-positive breast cancer

Abstract excerpt

Development of acquired resistance to targeted cancer therapy is one of the most significant clinical challenges. Acquiring resistance under drug selection pressure is a result of evolutionary adaptation to a complex and dynamic tumor microenvironment (TME). New therapy regimens combining CDK4/6 inhibitor are under active investigation in clinical trials to treat HER2+ breast cancer patients. In parallel with clin...

Topics

Open a Topic to create a Post that cites this publication.

• Breast Neoplasms
• Cells, Cultured
• Clonal Evolution
• Drug Resistance, Neoplasm
• Gene Expression Profiling
• Gene Expression Regulation, Neoplastic
• High-Throughput Nucleotide Sequencing
• Single-Cell Analysis

Identifiers and source

Literature Corpus work

8e716759-b0cb-5c41-9357-2969f5de02af

DOI

10.1101/671198